China Biologic Products Reports Record Sales and Net Income for 2010

Mar 31, 2011, 17:30 ET from China Biologic Products, Inc.

TAI'AN, SHANDONG PROVINCE, China, March 31, 2011 /PRNewswire-Asia-FirstCall/ --  China Biologic Products, Inc. (Nasdaq: CBPO) ("China Biologic" or the "Company"), one of the leading plasma-based biopharmaceutical companies in the People's Republic of China ("PRC"), today reported record sales and net income for the year ended December 31, 2010.

  • Sales increased $20.7 million or 17.4% to $139.7 million for the year ended December 31, 2010 from $119.0 million in 2009.
  • Gross profit increased $16.4 million or 18.9% to $102.7 million in 2010 from $86.4 million in 2009. Gross profit as a percent of sales increased to 73.5% in 2010 from 72.6% in 2009.
  • Income from operations increased $8.1 million or 13.3% to $69.5 million in 2010 from $61.4 million in 2009.
  • GAAP Net income attributable to China Biologic in 2010 was $31.5 million or $1.30 per diluted share, including a $3.2 million non-cash charge related to change in the fair value of derivative liabilities, compared with $2.2 million or $0.10 per diluted share in 2009, which includes a $28.9 million non-cash charge related to change in the fair value of derivative liabilities.
  • Non-GAAP adjusted net income was $39.0 million or $1.61 per diluted share in 2010 compared with $31.5 million or $1.43 per diluted share in 2009.

In addition, China Biologic announced that it has restated the financial statements for the year 2009 and will restate the financial statements for the interim periods for years 2009 and 2010 as soon as practical which will be set forth in its Annual Report on Form 10-K for the year ended December 31, 2010 and the amendments to the periodic reports for the affected periods. The revisions were made primarily to correct: (1) inadvertent omission of the fair value of the callable features embedded in the warrants issued on July 19, 2006 (the "2006 Warrants") and (ii) misinterpretation of US GAAP regarding recognition of deferred tax liabilities related to the acquisition of Guiyang Dalin Biologic Technologies Co., Ltd. ("Dalin") in 2009 (the "Dalin Acquisition"). The Company expects that the restatement will not have an effect on the Company's liquidity, cash resources, or future business operations because they are all noncash adjustments.

CEO comments

Mr. Chao Ming (Colin) Zhao, Chief Executive Officer of China Biologic, said, "We are pleased with our progress and good operating and financial results for 2010. We believe our acquisitions from 2008 and 2009 are starting to deliver the expected good performance."

"We believe that our strategy of direct institutional sales remains the good long-term model for serving our customers for our products and markets in China. When we acquired Dalin, we converted its sales model to direct institutional sales from sales conducted mainly through distributors. In 2010, direct institutional sales of Dalin did not grow as quickly as we expected. We will continue to strengthen Dalin's direct institutional sales approach in 2011.

"We have restated our financial statements for the year 2009 and will restate the financial statements for the interim periods for years 2009 and 2010 due to adjustments to certain non-cash items below our operating income line, which are mainly associated with the evaluation of the fair market value of the callable feature of our warrants previously issued in 2006 and deferred tax liabilities in connection with the Company's prior acquisition of Dalin. We believe these adjustments will not negatively affect our operations and affect our ability to be successful in our business, expand our market share, generate free cash flow, or achieve our long-term strategic goals.

"With the continuing expansion of China's economy, China Biologic's outlook for 2011 remains good. We believe higher health standards will continue to be among the government's priorities. And our plasma collection stations and processing facilities are in good locations and are operating at high standards.

"In addition, we have completed the development stages for two new products and expect their approval by China's State Food and Drug Administration in 2011.

"We expect to continue to grow our business, primarily by internal growth and, when appropriate, by prudent acquisitions that can enlarge our geographic operations or provide natural extensions of our current product lines. We look forward to the year 2011 with confidence and determination."

The 2010 financial results presented below reflect the restatement made for fiscal year 2009. For a more detailed information about the restatements, please see below under the heading "Restatements of the financial statements for year 2009 and the interim periods for years 2009 and 2010."

Results for the year 2010

Revenues increased 17.4% or $20.7 million to $139.7 million in 2010 from $119.0 million in 2009 due mainly to a general increase in the price and volume of plasma based products.

Sales from human albumin product rose approximately 13.4% year-over-year to approximately $67.1 million, accounting for approximately 48.0% of the total sales in 2010, as compared to approximately 49.7% in 2009. Sales volume of human albumin products increased approximately 15.7% in 2010 as compared to 2009, while average selling price ("ASP") of human albumin decreased by1.8%. The price decrease in human albumin is due to the increased in volume of imported human albumin products in 2010 and we believe the trend may continue as long as the volume of the imported human albumin products continue to grow. Sales from human immunoglobulin for intravenous injection ("IVIG") grew approximately 9.6% to approximately $48.0 million in 2010 and represented approximately 34.3% of the total sales, as compared to approximately 36.8% of total sales in 2009. Increase in sales from IVIG was mainly due to an approximately 26.9% increase in ASP which was partially offset by an approximately 15.8% decrease in sales volume. Sales from the human tetanus immunoglobulin products rose approximately 55.8% to approximately $4.1 million, contributing approximately 2.9% of total sales in 2010 as compared to approximately 2.2% in 2009. Sales volume and ASP for human tetanus immunoglobulin increased approximately 24.6% and 12.6%, respectively. Sales from human hepatitis B immunoglobulin rose approximately 206.7% to approximately $10.6 million, contributing approximately 7.6% of the total sales in 2010 as compared to approximately 2.9% in 2009. Sales volume and ASP for human hepatitis B immunoglobulin increased approximately 7.4% and 186.4% in 2010, respectively. Sales from human rabies immunoglobulin rose approximately 57.2% to $7.5 million, contributing approximately 5.3% of total sales in 2010 as compared to approximately 4.0% in 2009. Sales volume and ASP for sales human rabies immunoglobulin increased 26.5% and 24.6% in 2010, respectively.

Gross profit increased $16.4 million or 18.9% to $102.7 million in 2010 from $86.4 million in 2009. Gross profit margin was 73.5% in 2010, as compared to 72.6% in the prior year.

Total operating expenses in 2010 increased 32.9% to $33.2 million, as compared to $25.0 million in the prior year. As a percentage of total sales, total expenses increased to 23.8% in 2010 from 21.0% in 2009.

Selling expenses increased 108.9% to $7.4 million in 2010 from $3.5 million in 2009. As a percentage of total sales, selling expenses increased to 5.3% in 2010 from 3.0% in 2009. The increase in selling expenses was primarily due to the increased marketing efforts in connection with strengthening our direct institution sales approach.

General and administrative ("G&A") expenses increased 18.7% to $23.5 million in 2010. As a percentage of total sales, G&A expenses were 16.8% and 16.6% for 2010 and 2009, respectively.  The dollar increase in G&A expenses was mainly due to higher expenses in professional services, non-cash employee compensation, travel, and general office expenses as we continue our efforts in integrating our two main operating entities, and an increased amount of inventory allowance for reserving non-useable plasma in connection with 90 day plasma quarantine rules implemented by China SFDA in July 2008. The Company incurred $2.3 million in non-cash employee compensation in 2010, as compared to $62,281 in 2009.

Research and development expenses increased 40.5% to $2.3 million, or 1.7% of total sales in 2010, as compared to $1.7 million, or 1.4% in 2009. The dollar increase was primarily due to the costs associated with the development of two new products that are at the end of their development stages.

Income from operations increased 13.3% to $69.5 million or 49.8% of total sales in 2010, as compared to $61.4 million, or 51.6% in 2009.

Total loss related to change in fair value of derivative liabilities in 2010 was $3.2 million, as compared to $28.9 million in the prior year. Net interest expense decreased to $1.9 million in 2010 from $3.9 million in 2009, primarily due to the related party loan associated with the Dalin Acquisition being paid off in the second quarter of 2010.

The provision for income taxes increased 35.9% to $13.6 million in 2010, from $10.0 million in 2009. The effective tax rate in 2010 was 20.7%, as compared to 34.7% in 2009. The decrease in effective tax rate was mainly due to lower non-tax deductible charges of $25.7 million in the change in fair value of derivative liabilities as compared to the 2010.

GAAP net income attributable to China Biologic in 2010 was $31.5 million, or $1.30 per diluted share, as compared to $2.2 million, or $0.10 per diluted share, in 2009. Non-GAAP adjusted net income was $39.0 million, or $1.61 per diluted share, in 2010, as compared to $31.5 million, or $1.43 per diluted share, in 2009. Non-GAAP adjusted net income and diluted earnings per share in 2010 excluded an aggregate of $7.4 million charges, which are related to change in the fair value of derivative liabilities and non-cash employee compensation expenses after adding back interest related to the convertible notes under the if-converted method. Please see the table at the end of the release that reconciles our non-GAAP measures with the nearest comparable GAAP measures.

Financial Condition

As of December 31, 2010, the Company had $64.9 million in cash and cash equivalents, approximately $61.4 million in working capital, and a current ratio of 185.9%. Total shareholder's equity on December 31, 2010 was $145.0 million, as compared to $84.1 million at the end of 2009. The Company generated $38.8 million in net cash from operating activities in 2010 as compared to $50.3 million in 2009.

Guidance and business outlook for 2011

China Biologic expects 2011 revenue to be in the range of $154 million and $168 million. This guidance assumes only organic growth and excludes acquisitions and construction of new facilities. The guidance necessarily assumes no significant adverse price changes during 2011.

The Company expects 2011 adjusted net income to be in the range of $41 million to $43 million, excluding any non-cash charge or gain related to change in the fair value of derivative liabilities and stock-based compensation expense and any adjustments in the U.S. federal income tax provision in 2011 related to the expiration of the look-through exception for Subpart F income on December 31, 2011. To support its business expansion, the Company expects to have substantially higher expenses in 2011 to expand its geographic market coverage, add new customers, and increase direct sales to institutional customers of its products. Due to the expected expense increase associated with our marketing and sales efforts, we anticipate modest growth in adjusted net income for 2011 despite anticipated growth in sales in 2011.

As a corporate policy, the Company does not intend to update this guidance during the year unless required by the applicable laws. This forecast reflects the Company's current and preliminary views, which are subject to change.

Restatements of the financial statements for year 2009 and the interim periods for years 2009 and 2010

The Company's audit committee has determined that it will restate its previously issued financial statements for the year 2009 and the interim periods for years 2009 and 2010 to reflect the correction of accounting errors in connection with reevaluation of the accounting treatments for two issues: (1) inadvertently omission of the fair value of callable feature embedded in the 2006 Warrants; and (2) misinterpretation of US GAAP regarding the recognition of deferred tax liabilities in connection with the Dalin Acquisition.

Recognition of fair value of the callable feature for the 2006 Warrants

In 2006, the Company issued 1,070,000 warrants to certain accredited investors. According to the terms of the 2006 Warrants, the Company may, in its sole discretion, elect to require the 2006 Warrants holders to exercise up to all of the unexercised portion of the 2006 Warrants ("Callable Feature").  The Company inadvertently omitted the fair value of the Callable Features embedded in the 2006 Warrants when reclassifying the fair value of 2006 Warrants from equity to derivative liabilities as of January 1, 2009 while adopting EITF 07-5, "Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity's Own Stock" (FASB ASC 815-40-15-5) (or "EITF 07-05").  As a result, the retained earnings and additional paid-in capital should have been increased by $535,615 and $138,160, respectively, and the derivative liabilities should have been decreased by $673,775 as of January 1, 2009. During the year ended December 31, 2009, all of the 2006 Warrants were exercised.  The Company inadvertently omitted recognizing the impact of fair value change arising from the Callable Feature in estimating the fair value of the 2006 Warrants during 2009.  As a result, the loss of change in fair value of derivative liabilities during the year ended December 31, 2009 should have been decreased by $710,861. The retained earnings and additional paid-in capital should have been increased by $1,246,476 and decreased by $1,246,476, respectively, as of December 31, 2009.

Recognition of deferred tax liabilities in connection with the Dalin Acquisition

In connection with the Dalin Acquisition in 2009, the Company misinterpreted US GAAP regarding the accounting for the business combination. As a result, the Company did not recognize deferred tax liabilities for differences between the assigned values and the tax bases of the intangible assets and certain property, plant and equipment acquired in the Dalin Acquisition in accordance with ASC Topic 740, Income Taxes. As of January 1, 2009, deferred tax liabilities of $4,749,099 should have been recognized with a corresponding increase in goodwill of $4,749,099. During the year ended December 31, 2009, the Company also should have recorded deferred tax benefit representing the tax effect of the amortization of intangible assets and the depreciation of property, plant and equipment for the year ended December 31, 2009. As a result, the goodwill, deferred tax liabilities, retained earnings, noncontrolling interest and accumulated other comprehensive income of the Company should have been increased by $4,775,139, $4,275,295, $232,368, $267,333 and $143, respectively, as of December 31, 2009.

Conference call

China Biologic will host a dial-in conference call at 7:00 a.m. EDT (New York) on Friday, April 1, 2011, to discuss its results for 2010. To participate in the conference call, please dial the appropriate number about 10 minutes prior to the scheduled conference call time:

The dial-in details for the live conference call are:

U.S. toll-free number

1 866 549 1292

Mainland China toll-free number

400 681 6949

Hong Kong local access

3005 2050

International toll number

+852 3005 2050

Participant pass code

674 477#



A telephone replay of the call will be available after the conclusion of the conference all through 8:00 a.m. EDT on April 8, 2011.

The dial-in details for the telephone replay are:

U.S. toll-free number

1 866 753 0743

Mainland China toll free number

800 876 8594

Hong Kong local access

3005 2020

International dial-in toll number  

+852 3005 2020

Replay pass code

138 012#



Use of non-GAAP financial measures

This press release contains non-GAAP financial measures that exclude non-cash compensation expenses related to options granted to employees and directors under the Company's 2008 Equity Incentive Plan and changes in the fair value of derivative liabilities, including warrants and derivative instruments (including the conversion option) embedded in the Company's Senior Secured Convertible Notes (after adding back interest related to the convertible notes under the if-converted method). To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information excluding the impact of this item in this release. The Company's management believes that these non-GAAP measures provide investors with a better understanding of how the results relate to the Company's historical performance. A reconciliation of the adjustments to GAAP results appears in the table accompanying this press release. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies.

About China Biologic Products, Inc.

China Biologic Products, Inc., through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd, and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is currently the largest non-state-owned plasma-based biopharmaceutical company in China. The Company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The Company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies, and are used for the prevention and treatment of various diseases. The Company sells its products to hospitals and other healthcare facilities in China. Please see the Company's website www.chinabiologic.com for additional information.

Safe harbor statement

This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiaries. All statements, other than statements of historical fact included herein are "forward-looking statements," including, among others, statements regarding: the Company's expected financial performance in 2011 and our ability to deliver such results; our new products and expected government approval,; the Company's ability to build new or expand existing plasma collection stations; expected growth in Chinese economy and our business, our expected financial performance and strategic and operational plans, our future operating results, our expectations regarding the market for our products, as well as all assumptions, expectations, predictions, intentions or beliefs about future events.. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Financial statements follow.

CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME





For the Years Ended





December 31, 2010


December 31,2009












Sales








           External customers


$

138,674,983

$

118,293,137



           Related party



1,020,434


705,018



Total sales



139,695,417


118,998,155











Cost of sales








           External customers



36,793,775


32,544,743



           Related party



157,374


77,165



Cost of sales



36,951,149


32,621,908











Gross profit



102,744,268


86,376,247











Operating expenses








           Selling expenses



7,372,348


3,529,242



           General and administrative expenses



23,510,566


19,807,123



           Research and development expenses



2,336,126


1,662,690











Income from operations



69,525,228


61,377,192











Other expenses/(income)








           Equity in income of equity method investee



(1,070,241)


(566,984)



           Change in fair value of derivative liabilities



3,233,288


28,915,328



           Interest expense, net



1,930,165


3,930,249



           Other (income)/expense, net



(169,043)


261,252



Total other expenses, net



3,924,169


32,539,845











Earnings before income tax expense



65,601,059


28,837,347











Income tax expense



13,608,755


10,013,563











Net income



51,992,304


18,823,784











Less: Net income attributable to the noncontrolling interest



20,449,421


16,615,658











Net income attributable to China Biologic Products, Inc.



31,542,883


2,208,126











Earnings per share:








           Basic


$

1.34

$

0.10



           Diluted


$

1.30

$

0.10











Weighted average shares used in computation:








           Basic


$

23,586,506

$

21,754,911



           Diluted


$

24,176,432

$

21,949,638






CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS




December



December





31, 2010



31, 2009










ASSETS








Current Assets








   Cash and cash equivalents


$

64,941,368


$

53,843,951


   Accounts receivable, net of allowance for doubtful accounts



9,922,111



1,767,076


   Accounts receivable - a related party



212,611



222,617


   Inventories



52,300,447



35,132,724


   Other receivables



2,727,110



2,186,441


   Prepayments and prepaid expenses



855,338



1,299,125


   Deferred tax assets



1,860,753



1,053,771


       Total Current Assets



132,819,738



95,505,705










Property, plant and equipment, net



39,511,731



28,873,413


Intangible assets, net



14,559,020



17,200,512


Land use right, net



4,701,450



3,979,810


Prepayments for non-current assets



4,254,423



3,223,960


Goodwill



17,778,231



17,200,728


Equity method investment



7,297,201



6,627,355


       Total Assets


$

220,921,794


$

172,611,483










LIABILITIES AND STOCKHOLDERS' EQUITY








Current liabilities








   Short-term bank loans


$

3,034,000


$

4,401,000


   Short term loans - noncontrolling interest



-



3,652,500


   Accounts payable



4,392,772



3,750,441


   Due to related party



3,192,140



3,086,940


   Other payables and accrued expenses



21,606,730



21,516,116


   Accrued interest - noncontrolling interest  



-



2,068,526


   Advance from customers



3,560,018



3,868,577


   Income tax payable



6,659,805



7,479,279


   Other taxes payable



2,146,868



1,294,800


Convertible notes



1,196,233



89,760


Derivative liabilities - embedded conversion option in convertible notes



14,561,661



19,960,145


Derivative liabilities - warrants



11,095,592



12,701,262


       Total Current Liabilities



71,445,819



83,869,346


Other payable



333,008



323,687


Deferred tax liabilities



4,098,834



4,275,295


       Total Liabilities



75,877,661



88,468,328










Stockholder's Equity








Common stock: par value $.0001; 100,000,000 shares authorized; 24,351,126 and 23,056,442 shares issued and outstanding at December 31, 2010 and 2009, respectively



2,435



2,305


   Additional paid-in capital



35,435,139



21,270,601


   Retained earnings



55,739,101



24,196,218


   Accumulated other comprehensive income



8,023,121



4,227,537


       Total stockholder's equity attributable to China Biologic Products, Inc.



99,199,796



49,696,661










   Noncontrolling interest



45,844,337



34,446,494










       Total Stockholder's Equity



145,044,133



84,143,155










   Commitments and contingencies



-



-










       Total Liabilities and  Stockholder's Equity


$

220,921,794


$

172,611,483





CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS




2010



2009


CASH FLOWS FROM OPERATING ACTIVITIES:







   Net income


51,992,304



18,823,784


   Adjustments to reconcile net income to cash provided by operating activities:







           Depreciation


3,607,184



2,709,623


           Amortization


3,566,269



3,358,532


           Loss on sale of property, plant and equipment


120,224



224,548


           Reversal of allowance for doubtful accounts, net


(57,624)



(13,089)


           Provision for doubtful accounts - other receivables and prepayments


475,346



280,796


           Write-down of obsolete inventories


451,761



519,333


           Deferred tax benefit, net


(1,101,171)



(1,552,661)


           Stock compensation


2,341,783



62,281


           Change in fair value of derivative liabilities


3,233,288



28,915,328


           Amortization of deferred note issuance cost


258,753



247,199


           Amortization of discount on convertible notes


1,590,740



100,253


           Equity in income of equity method investee


(1,070,241)



(566,984)


      Change in operating assets and liabilities, net of acquisition in Dalin:







           Accounts receivable – third parties


(7,837,681)



(1,707,714)


           Accounts receivable - related party


17,158



197,284


           Other receivables


182,686



(1,744,794)


           Inventories


(16,026,215)



(12,456,975)


           Prepayments and prepaid expenses


(91,307)



(248,794)


           Accounts payable


505,407



(58,467)


           Other payables and accrued expenses


(596,938)



7,058,773


           Accrued interest - noncontrolling interest shareholders


(2,086,010)



2,068,526


           Advance from customers


(429,497)



274,768


           Income tax payable


(1,046,906)



2,943,767


           Other taxes payable


787,913



865,670


Net cash provided by operating activities


38,787,226



50,300,987









CASH FLOWS FROM INVESTING ACTIVITIES:







   Dividends received


-



384,087


   Acquisition of a subsidiary, net of cash acquired


(4,063,325)



1,573,079


   Acquisition of equity method investment


-



(3,225,420)


   Purchase of property, plant and equipment


(10,313,432)



(3,522,768)


   Purchase of intangible assets and land use right


(1,474,718)



(2,106,203)


   Proceeds from sale of property, plant and equipment


-



36,771


Net cash used in investing activities


(15,851,475)



(6,860,454)





CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS




2,010


2,009






CASH FLOWS FROM FINANCING ACTIVITIES:





   Proceeds from warrants exercised


1,232,482


3,649,770

   Proceeds from option exercised


97,600


350,000

   Proceeds from issuance of convertible notes


-


8,967,516

   Repayments of former shareholders loan in a subsidiary


-


(2,841,302)

   Proceeds from short term bank loans


5,917,600


13,536,688

   Repayment of short term bank loans


(7,397,000)


(18,355,572)

   Repayment of loan from noncontrolling interest holder


(3,683,373)


(772,803)

   Dividends paid by subsidiaries to noncontrolling interest shareholders


(10,446,179)


(2,969,372)

Net cash (used)/provided by financing activities


(14,278,870)


1,564,925

EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH


2,440,536


23,877






NET INCREASE IN CASH


11,097,417


45,029,335






Cash and cash equivalents at beginning of year


53,843,951


8,814,616






Cash and cash equivalents at end of year

$

64,941,368

$

53,843,951






Supplemental cash flow information





   Cash paid for income taxes

$

15,756,832

$

8,021,981

   Cash paid for interest expense (net of capitalized interest)

$

810,643

$

1,131,271

   Noncash investing and financing activities:





       Reclassification of warrant liability to paid-in capital upon warrants conversion

$

3,045,611

$

4,921,639

       Convertible notes conversion

$

7,191,763

$

2,187,330

       Distribution paid by offsetting accounts receivable - related party

$

-

$

944,036

       Distribution paid in exchange of noncontrolling interest shareholders loan

$

-

$

3,665,250

       Distribution paid by offsetting loan and interest due from holder of

$

-

$

4,647,924

noncontrolling interest

       Net assets acquired with prepayments made in prior periods

$

-

$

14,250,492

       Net assets acquired with unpaid investment

$

-

$

2,850,098

       Property, plant and equipment acquired with prepayments made in prior periods

$

1,078,348

$

2,296,113

       Land use right acquired with prepayments made in prior periods

$

-

$

146,610



CHINA BIOLOGIC PRODUCTS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY AND COMPREHENSIVE INCOME










Accumulated other






Common stock


Additional


Retained


comprehensive


Noncontrolling




Shares


Par value


paid-in capital


earnings


income


interest


Total equity





























Balance as of January 1, 2009

21,434,942

$

2,143

$

10,700,032

$

22,382,054

$

4,159,298

$

4,805,381

$

42,048,908

  Cumulative effect of reclassification of 2006 Warrants (see Note 14)

-


-


(600,289)


(393,962)


-


-


(994,251)

Balance as of January 1, 2009 (reclassified)

21,434,942

$

2,143

$

10,099,743

$

21,988,092

$

4,159,298

$

4,805,381

$

41,054,657















   Net income

-


-


-


2,208,126


-


16,615,658


18,823,784

   Foreign currency translation adjustments, net of nil income taxes

-


-


-


-


68,239


455,788


524,027

   Comprehensive income













19,347,811















Dividends declared by subsidiaries to noncontrolling interest



-


-


-


-


(8,955,392)


(8,955,392)

Acquisition of Dalin

-


-


-


-


-


21,525,059


21,525,059

   Stock compensation

-


-


62,281


-


-


-


62,281

Common stock issued in connection with:














      - Exercise of warrants

1,284,000


128


8,571,281


-


-


-


8,571,409

      - Exercise of stock option

87,500


9


349,991


-


-


-


350,000

      - Conversion of convertible notes

250,000


25


2,187,305


-


-


-


2,187,330

Balance as of December 31, 2009

23,056,442

$

2,305

$

21,270,601

$

24,196,218

$

4,227,537

$

34,446,494

$

84,143,155















   Net income

-


-


-


31,542,883


-


20,449,421


51,992,304

   Foreign currency translation adjustments, net of nil income taxes

-


-


-


-


3,795,584


1,381,931


5,177,515

 Comprehensive income













57,169,819















   Dividend declared by subsidiaries to noncontrolling interest

-


-


-


-


-


(10,446,179)


(10,446,179)

   Acquisition of noncontrolling interests

-


-


-


-


-


12,670


12,670

   Stock compensation

-


-


2,341,783


-


-


-


2,341,783

Common stock issued in connection with:














      - Exercise of warrants

294,019


30


4,278,160


-


-


-


4,278,190

     - Exercise of stock option

37,130


4


97,596


-


-


-


97,600

     - Conversion of convertible notes

963,535


96


7,446,999


-


-


-


7,447,095

Balance as of December 31, 2010

24,351,126

$

2,435

$

35,435,139

$

55,739,101

$

8,023,121

$

45,844,337

$

145,044,133



Non-GAAP to GAAP reconciliation table


Fiscal Year Ended December 31, 2010

Fiscal Year Ended December 31, 2009

Net Income (Loss) Diluted EPS

Net Income

Diluted EPS

Net Income

Diluted EPS

Adjusted Net Income - Non GAAP

$38,967,447

$1.61

$31,487,745

$1.43

Non-cash employee compensation (1)

$2,341,783

$0.10

$62,281

$0.00

Loss in fair value of derivative liabilities (2)

$3,233,288

$0.13

$28,915,328

$1.32

Interest of Convertible Notes  (3)

$1,849,493

$0.08

$302,010

$0.01

Net Income attributable to controlling interest

$31,542,883

$1.30

$2,208,126

$0.10

Weighted average number of Shares

24,176,432


21,949,638





Company Contact

Mr. Y. Tristan Kuo

Chief Financial Officer

China Biologic Products, Inc.

Telephone: +86-538-6202206

Email: ir@chinabiologic.com

www.chinabiologic.com



SOURCE China Biologic Products, Inc.



RELATED LINKS

http://www.chinabiologic.com